Note: Descriptions are shown in the official language in which they were submitted.
204035;~
ARC 1649
POLYISOBUTYLENE ADHESIVES FOR TRANSDERMAL DEVICES
Technical Field
s The invention herein pertains to polyisobutylene (PIB) adhesives
useful in transdermal drug delivery systems.
Backqround Art
Transdermal devices for delivery of a variety of biologically
active agents through the skin or mucosa are known to the art.
Representative systems which use rate controlling membranes and in-line
adhesives (i.e., adhesives disposed in the path of drug or agent
migration from the reservoir to the skin) are disclosed in U.S. Patents
3,598,122; 3,598t123; 3,742,951; 4,031,894; 4,060,084; 4,144,317;
4,201,211; and 4,379,454. Subsaturated transdermal devices are
disclosed in U.S. Patent 4,379,454. U.S. Patent 4,286,592 describes a
transdermal drug delivery device in which the PIB/MO adhesive is less
permeable to the drug being delivered than is the reservoir layer. The
20 limited permeability adhesive layer acts as a rate-controlling member.
When in-line adhesives are used in transdermal delivery devices
it is necessary that they exhibit a reasonable permeability to the
agent being delivered and, when they are used in combination with a
25 rate-controlling membrane, the adhesive layer preferably exhibits a
higher permeability to the drug than the rate controlling membrane.
Mixtures of high and low molecular weight polyisobutylenes (PIB)
are known to the art as adhesives, however they are relatively
30 impermeable to many drugs. As a result, the prior art in-line PIB
adhesives usually contain a plasticizer such as mineral oil (MO) or
polybutene to achieve sufficient permeability to permit drug migration
through the adhesive at rates which are therapeutically useful from
reasonably sized systems.
2(140352
ARC 1649
A typical formulation of the prior art uses a ratio of 1.2M
molecular weight (MW) PIB:35K MW PIB:MO of about 1:1.125:2. In such a
formulation the high molecular weight (HMW) PIB acts as an adhesive
base, the low molecular weight (LMW) PIB acts as tackifier, and the
s mineral oil acts to plasticize the adhesive and to increase the
permeability of the adhesive composition to the drug.
It is also known to include tackifiers to improve the adhesive
characteristics of medical adhesives. For example, Australian
application AU-A-57457/86 discloses a self adhesive matrix for
delivering nitroglycerin which comprises a mineral oil-free mixture of
high and low molecular weight PIB's with a resinous tackifier. Such
tackifiers are often natural resinous or rosinous products of undefined
compositions. Both mineral oil and tackifiers vary in their detailed
composition from batch to batch and may unpredictably contain
components which are irritating or sensitizing to the skin.
.
Many medically acceptable contact adhesives of the prior art are
ineffective in the transdermal delivery of acti-ve agents which are
20 highly soluble in the adhesives. When the agent has a high solubility
in the adhesive layer, substantial quantities of agent migrate from the
reservoir through the rate controlling membrane and into the adhesive
layer as the device equilibrates over time. The migration continues
until the thermodynamic activity of the agent in the adhesive equals
25 the thermodynamic activity of the agent in the reservoir. As a result,
the large quantity of the active agent in the adhesive layer is
released onto the skin without control bx the rate controlling
membrane, which can only exert an effect on the agent which remains in
the reservoir. High concentrations of agent in direct contact with the
30 skin can also cause irritation, or produce undesirably high initial
plasma levels of the agent.
Many medically acceptable contact adhesives of the prior art are
also ineffective in conjunction w;th agents which are capable of
35 plasticizing, solvating, or otherwise causing the adhesive to lose its
204035~
ARC 1649
cohesiveness. Such agents, which are typically oily, non-polar
components such as nicotine, benztropine, secoverine, dexsecoverine and
arecoline, for example, can destroy the adhesive properties of a
transdermal patch, causing premature detachment of the system. U.S.
s Patents 4,597,961 and 4,839,174, the disclosures of which are
incorporated herein by reference, disclose transdermal nicotine
delivery devices in which nicotine is present in the reservoir. The
device of 4,597,561 uses a peripheral adhesive to avoid this type of
problem. Copending, commonly assigned U.S. Application Serial
No. 07/206,546, filed June 14, 1988, the disclosure of which is
incorporated herein by reference, describes a transdermal nicotine
delivery system using a subsaturated reservoir to cope with this
problem.
Mineral oil is also soluble in some common components of
transdermal systems, such as ethylene vinyl acetate (EVA) copolymers
and may migrate from the adhesive layer into these materials over time.
The loss of the plasticizing mineral oil in the adhesive can cause
changes in the physical properties of the adhesive compound, adversely
20 affecting the performance of the adhesive.
According to our invention, it has unexpectedly been discovered
that certain agents, in the presence of which traditional transdermal
non-PIB adhesives are plasticized, solvated, or lose their adhesive
25 properties, can be delivered from a transdermal delivery device using
the in-line PIB adhesives of this invention which are substantially
free of tackifiers and plasticizers.
It is therefore an object of this invention to provide a new and
30 useful in-line adhesive for use in transdermal delivery devices.
It is another object of this invention to provide in-line
adhesives for transdermal delivery devices which are useful in delivery
of agents which have an undesirably high solubility in prior in-line
35 adhesives.
2040~5?~
ARC 1649
It is another object of the invention to provide a PIB adhesive
substantially free of plasticizers and tackifiers.
It is yet another object of this invention to provide an in-line
s adhesive in a transdermal delivery device which rapidly reaches
equilibrium after manufacture.
It is yet another object of the invention to provide a
transdermal delivery system using high and low molecular weight PIB
o substantially free of plasticizers and tackifiers, as an in-line
adhesive.
It is another object of this invention to provide PIB adhesives
substantially free of plasticizers and tackifiers having a high
permeability for the agent to be delivered, and which are suitable as
an in-line adhesives in transdermal delivery devices having a release
rate controlling membrane.
It is another object of this invention to provide an in-line
20 adhesive for use in a transdermal delivery device which is relatively
non-irritating, is inexpensive, can be used in the delivery of oily,
non-polar active agents.
Brief Description of the Invention
The invention comprises an adhesive which is useful as an in-line
adhesive in transdermal delivery devices. .The adhesive comprises
mixtures of high molecular weight (HMW) and low molecular weight (LMW)
PIBs in weight ratios of about 5-40 HMW PIB:95-60LMW PIB which are
30 substantially free of plasticizers and tackifiers. In use, the
adhesive will also contain dissolved active ~gent at a concentration
which is in equilibrium with the concentration of agent in the
reservoir.
204035~
ARC 1649
The adhesive finds particular use as a component of a transdermal
delivery device for delivery of active agents which solvate,
plasticize, or adversely affect the adhestve properties of conventional
in-line adhesives. Such agents include nicotine, benztropine,
s secoverine, dexsecoverine, or arecoline for example.
Disclosure of Invention Including Best Mode
The adhesives of this invention are in-line adhesives for
o transdermal delivery devices, i.e., the agent being delivered by the
system is transported through the adhesive prior to reaching the
surface of the skin. In its broadest application, the adhesives of
this invention can be used in monolithic transdermal delivery devices
which comprise a thin film of the agent dispersed in the adhesive which
is normally provided with a protective, agent-impermeable backing
layer. In this embodiment, the adhesive layer functions as both the
agent reservoir and the adhesive.
The adhesives of this invention could also be used as release
rate-controlling adhesives such as are shown in U.S. patent 4,286,592
which is incorporated herein by reference, in which an adhesive coating
on the drug reservoir functions to control release rate and maintain
the device on the skin.
The characteristics of the adhesives of this invention, however,
make them particularly useful as in-line adhesives in rate controlled
transdermal delivery devices which generally comprise, an adhesive
layer, a reservoir containing the agent to be delivered and rate-
controlling means disposed between the reservoir and adhesive and an
30 agent-impermeable backing layer. A strippable release liner preferably
covers the adhesive layer during storage of t~e device and is removed
prior to use. Transdermal delivery devices are applied to a patient
for a predetermined administration period, which can range from several
hours up to a week depending upon the agent being delivered and the
35 condition being treated.
204035 .~4
ARC 1649
The term, "agent" as used herein, refers to any beneficial agent
or compound that can be delivered by a device herein to produce a
beneficial and useful result. The term includes medicines, organic and
inorganic drugs, hormones, nutrients, vitamins, food supplements, and
s other agents that benefit an animal or human. It is to be understood
that more than one agent may be delivered from a device using the
adhesives of this invention, and that the use of the term "agent" in no
way excludes the use of two or more such agents.
The term, "plasticizer" as used herein, refers to compounds other
than the agent being delivered, such as mineral oil, polybutene oil,
and other low molecular weight hydrocarbons that act to plasticize PIB
adhesives and increase their permeability to the agent being delivered.
An adhesive composition is substantially free of plasticizer if it
15 contains, at most, trace amounts of plasticizer and more preferably, no
plasticizer.
The term, atackifier" as used herein, refers to materials other
than PIB that are added to adhesives to increase their tack or
20 stickiness. Such materials are typically natural occurring resinous or
rosinous materials or truly synthetic polymer materials. An adhesive
is substantially free of tackifier if it contains, at most, trace
amounts of tackifier and preferably no tackifier.
The term, "high molecular weight polyisobutylene" (HMW PIB)
refers to a polyisobutylene composition having an average molecular
weight in the range of about 450,000 to about ~,100,000 and preferably
from about 990,000 to about 1,600,000.
The term, "low molecular weight polyisobutylene" (LMW PIB) refers
~o a polyisobutylene composition having an average molecular weight in
the range of about 1,000 to about 450,000, and preferably from about
35,000 to about 50,000.
2040~5~
ARC 1649
The adhesive composition of this invention contains the HMW and
LMW PIB in weight ratios (HMW PIB:LMW F'IB) in the range of about 5-
40:95-60, preferably in the range of about 10-25:90-75 and most
preferred in the range of about 10-20:90-80. The ratio of HMW PIB to
s LMW PIB which provides an optimal adhesive for a specific agent will be
dependent upon the identity and concentration of agent being delivered.
It is preferable that extraneous components of the adhesives of
this mixture be minimized or eliminated in order to minimize the
potential for irritation or allergic reaction when the transdermal
delivery system contacts the skin. However dyes, pigments, inert
fillers, stabilizers, stiffeners such as colloidal silicon dioxide, or
other additives other than plasticizers and tackifiers well known to
the art may be added if desired.
The thickness of the adhesive layer will generally be between
about 1 mil (0.0254 mm) and about 15 mil (0.381 mm) when used with a
rate-controlling membrane. The composition and thickness of the
adhesive layer will be adjusted such that the adhesive layer does not
20 constitute a significant permeation barrier to the passage of the agent
to be delivered as compared to that of the rate-controlling membrane.
Unless the drug involved requires the use of a loading dose to rapidly
saturate drug delivery sites in the skin, the thickness is also
preferably selected so that the adhesive does not contain a substantial
25 amount and preferably less than about 15% of the total amount of agent
in the device, particularly in rate-controlled delivery devices.
Transdermal delivery devices using the adhesives of this
invention may be of the monolithic or release rate-controlling adhesive
30 type but are preferably of the release rate-controlling membrane type
which comprise rate controlling means between the drug reservoir and
the in-line adhesive. The rate-controlling means acts to regulate the
flux of the agent being delivered to the skin and the rate controlling
element will have a lower permeability to the agent being delivered
35 than the adhesive layer. Materials which are appropriate for use with
204035~
ARC 1649
transdermal delivery systems are given in the patent application
U.S.S.N. 07/206,546, and in U.S. Patents 3,797,494 and 4,031,894, which
are incorporated herein by reference.
s The reservoir of such a transdermal delivery device contains one
or more agents to be delivered, dispersed within a matrix. Suitable
materials for the matrix of the reservoir include, without limitation,
natural and synthetic rubbers or other polymeric materials, petroleum
jelly or aqueous gels. When the agent being delivered is nicotine, a
preferred reservoir polymer matrix is fabricated from an ethylene-vinyl
acetate (EVA) copolymer such as is described in U.S. Patent 4,144,317,
preferably having a vinyl acetate content within the range of about 28
to 60 weight percent. Other embodiments of transdermal delivery
devices are known to the art and are also appropriate for use with the
15 adhesives herein. For example, the transdermal delivery devices shown
in U.S. Patents 3,598,123, and 4,588,580, the disclosures of which are
hereby incorporated by reference, can find application with the
adhesives disclosed herein.
zo The permeability of many agents through PIB is relatively low in
the absence of a plasticizer and for this reason the in-line PIB
adhesives of the prior art contained plasticizers such as mineral oil
or polybutene. We have found that certain agents, typically oily, non-
polar substances usually liquid at ambient temperatures, have
25 acceptable permeation through the plasticizer-free PIB adhesives of
this invention. It was also found that such agents, while highly
soluble in typical non-PIB adhesives of the prior art whose adhesive
properties are degraded by the concentrations of such agents
encountered, exhibit a relatively low solubility in the non-
30 plasticized PIB adhesives of this invention. As a result, the
concentration of agent which is present in ~he adhesive layer upon
equilibration is significantly reduced as compared to that observed in
prior art non-PIB adhesives. When used with such oily agents, this
significantly reduces the degradation caused by the agent, so that the
35 physical integrity and adhesive character;stics of the adhesives of
. ~ .
' ~
- . . ..
2040;~5%
ARC 1649
this invention are maintained. Oily, non-polar agents having the
desired properties include, without limitation, nicotine, benztropine,
secoverine, dexsecoverine and arec~line.-
s A backing layer prevents passage of the agent through the surface
of the reservoir distal to the skin, and provides support for the
system, if needed. The backing layer is impermeable or substantially
impermeable to the passage of the agent. It can be flexible or
nonflexible. Suitable materials are well known to the art and include,
o without limitation, polyethylene terephthalate, various nylons,
polypropylene, metallized polyester films, polyvinylidene chloride, and
aluminum foil.
A release liner can be included in the transdermal delivery
device as manufactured, as is well known in the art. The release lineris removed before the transdermal delivery device is applied to the
skin.
In a preferred embodiment a transdermal delivery device uses a
20 PIB adhesive of this invention together with a subsaturated reservoir
including nicotine.
The following examples are illustrative of the present invention
and they are not to be construed as limitations of the scope of the
25 invention. Variations and equivalents of these examples will be
readily apparent to workers skilled in the art in light of the present
disclosure. All ratios and percentages are on a weight basis, and all
temperatures are in degrees Celsius, unless otherwise noted.
ExamDle 1
PIB adhesives according to this invention were prepared as
follows:
, , . ' . ~ - ,
-
204035~
ARC 1649
Formula A: PIB having a MW of 35K was thoroughly blended with
PIB having a MW of 1.2M, in a weight ratio of HMW PIB:LMW PIB of 25:75.
Formula B: PIB having a MW of 35K was thoroughly blended with
s PIB having a MW of 1.2M, in a weight ratio of HMW PIB:LMW PIB of 20:80.
Formula C: PIB having a MW of 35K was thoroughly blended with
PIB having a MW of 1.2M, in a weight ratio of HMW PIB:LMW PIB of 15:85.
Formula D: PIB having a MW of 35K was thoroughly blended with
PIB having a MW of 1.2M, in a weight ratio of HMW PIB:LMW PIB of 10:90.
Example 2
Subsaturated transdermal drug delivery systems were made by
extruding a 0.13 mm thick drug reservoir film comprising a subsaturated
solution of 40tO nicotine base in 60% EVA (40% VA) between an
impermeable, pigmented aluminized polymer backing (Medpar~) and a high
density polyethylene (HDPE) rate-controlling membrane 0.05 mm thick.
20 This trilaminate was laminated to adhesives of Formulae B-D of Example
1 that were solvent cast from n-heptane solution onto a 0.076 mm
strippable release liner formed of fluorocarbon diacrylate/polyethylene
terephthlate, (3M 1022) and allowed to reach equilibrium. All samples
exhibited good adhesive properties and had 24 hour average in vitro
release rates into water at 37C of 60 ~g/cm2 hr, 70 ~g/cm2 hr, and
72 ~g/cm2 hr respectively.
.
Example 3
The procedures of Example 2 were repeated using the adhesive of
Formula A and substituting, as the drug reservDir, a mixture of 70 wt%
EVA-40 and 30 wt% nicotine base. The weight percent of the nicotine in
the adhesive upon equilibration was found to be about 11 weight
percent.
2040~
ARC 1649
11
The procedures of Example 2 were repeated, using the adhesive of
formula B with the above 70/30 EVA-40-nicotine reservoir. The weight
percent of nicotine in the adhesive-upon equilibration was also found
to be about 11 weight percent.
The procedures of Example 2 were repeated, using the adhesive of
Formula B, and reservoir composition of 20%, 30% and 40% nicotine base
in EVA-40. The weight percent of nicotine in the PIB adhesive after
equilibration was found to be as follows: 8 wt. percent in the 20%
nicotine reservoir device; 10 wt. percent in the 30% nicotine reservoir
device; and 14 wt. percent in the 40% nicotine reservoir device.
ExamPle 4
15 The procedures of Examples 2 and 3 are repeated substituting a 2
mil (0.0508 mm) low density polyethylene (LDPE) membrane for the HDPE
membrane and substituting for the nicotine reservoir solution, 10%
benztropine and 90% EVA-40 to produce transdermal devices for the
delivery of benztropine.
The devices will exhibit in vitro release rates into water at
37C of about 5-15 ~g/cm2 hr and will have good adhesive properties.
ExamPle 5
The procedures of Examples 2 and 3 are repeated, substituting for
the nicotine reservoir solution, 15% secoverine and 85% EVA-40 to
produce transdermal devices for the delivery of secoverine. The
devices will exhibit in vitro release rates into water at 37C of about
30 5-15 ~g/cm2 hr and will have good adhesive properties.
Example 6
The procedures of Examples 2 and 3 are repeated, substituting for
35the nicotine reservoir solution, 15% dexsecoverine and 85% EVA-40 to
2040352
ARC 1649
12
produce transdermal devices for the delivery of dexsecoverine. The
devices will exhibit in vitro release rates into water at 37C of about
5-15 ~g/cm2 hr and will have good adhesive properties.
Example 7
The procedures of Example 2 and 3 are repeated, substituting for
the nicotine reservoir solution, 40% arecoline and 60% EVA-40 to
produce transdermal devices for the delivery of arecoline. The device
will exhibit in vitro release rates into water at 37C of about 50-100
~g/cm2 hr and will have good adhesive properties.
While the present invention has been described with respect to
certain delivery devices, it will be apparent to one skilled in the art
15 that variations, modifications and substitutions can be made. These
variations, modifications and substitutions can be made without
departing from the scope of our invention, which is limited only by the
following claims.
